Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma

R F Barajas Jr, J L Rubenstein, J S Chang, J Hwang, S Cha, R F Barajas Jr, J L Rubenstein, J S Chang, J Hwang, S Cha

Abstract

Background and purpose: There is evidence that increased tumor cellular density within diagnostic specimens of primary central nervous system lymphoma (PCNSL) may have significant prognostic implications. Because cellular density may influence measurements of apparent diffusion coefficient (ADC) by using diffusion-weighted MR imaging (DWI), we hypothesized that ADC measured from contrast-enhancing regions might correlate with clinical outcome in patients with PCNSL.

Materials and methods: PCNSL tumors from 18 immunocompetent patients, treated uniformly with methotrexate-based chemotherapy, were studied with pretherapeutic DWI. Enhancing lesions were diagnosed by pathologic analysis as high-grade B-cell lymphomas. Regions of interest were placed around all enhancing lesions allowing calculation of mean, 25th percentile (ADC(25%)), and minimum ADC values. Histopathologic tumor cellularity was quantitatively measured in all patients. High and low ADC groups were stratified by the median ADC value of the cohort. The Welch t test assessed differences between groups. The Pearson correlation examined relationships between ADC measurements and tumor cellular density. Single and multivariable survival analysis was performed.

Results: We detected significant intra- and intertumor heterogeneity in ADC measurements. An inverse correlation between cellular density and ADC measurements was observed (P < .05). ADC(25%) measurements less than the median value of 692 (low ADC group) were associated with significantly shorter progression-free and overall survival. Patients with improved clinical outcome were noted to exhibit a significant decrease in ADC measurements following high-dose methotrexate chemotherapy.

Conclusions: Our study provides evidence that ADC measurements within contrast-enhancing regions of PCNSL tumors may provide noninvasive insight into clinical outcome.

Figures

Fig 1.
Fig 1.
Comparison of diffusion-weighted imaging (DWI) and cellular density between high and low apparent diffusion coefficient (ADC) groups (A and F). Contrast-enhanced T1-weighted image with regions of interest surrounding enhancing regions that were pathologically diagnosed as primary central nervous system non-Hodgkin lymphoma. Arrow indicates enhancing region subjected to stereotactic biopsy. DWI (B and G), black and white ADC map (C and H), color ADC map (D and I), and biopsy specimens (E and J) from patient 2 (low ADC group) and patient 17 (high ADC group) (hematoxylin-eosin, original magnification ×100).
Fig 2.
Fig 2.
Scatterplots of cellular density measurements versus 25th percentile (ADC25%, A) and mean ADC (ADCmean, B) values within contrast-enhancing tumor regions for all 18 subjects included in this study, demonstrating statistically significant inverse correlations (ADC25%, R = −0.47, P = .05; ADCmean, R = −0.54, P = .02).
Fig 3.
Fig 3.
A and B, Patient outcome as a function of ADC25% stratification into low and high groups. Kaplan Meier analysis (A) of progression-free survival (PFS) for patients stratified into the low ADC25% group (<692, blue line) with a mean progression time of 9.4 months versus those stratified into high ADC25% group (>692, red line) with a mean progression time of 30.0 months (P = .02, logrank test). Kaplan Meier plot (B) of overall survival (OS) for patients stratified into the low ADC25% group (<692, blue line) with a mean survival of 15.8 months versus those stratified into high ADC25% group (>692, red line) with a mean survival of 30.9 months (P = .01, logrank test). C and D, Patient outcome as a function of minimum ADC value shows a statistically significant difference in PFS and OS between low and high groups (P < .05).

References

    1. Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Hinsdale, Ilinois: Central Brain Tumor Registry of the United States; 2005
    1. Surawicz TS, McCarthy BJ, Kupelian V, et al. . Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. Neuro Oncol 1999; 1: 14–25
    1. Olson JE, Janney CA, Rao RD, et al. . The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002; 95: 1504–10
    1. Hochberg F, Baehring J, Hochberg E. Primary CNS lymphoma. Nat Clin Pract Neurol 2007; 3: 24–35
    1. Abrey LE, Batchelor TT, Ferreri AJ, et al. for the International Primary CNS Lymphoma Collaborative Group . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034–43. Epub 2005 Jun 13
    1. Glass J, Gruber ML, Cher L, et al. . Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188–95
    1. Gavrilovic IT, Hormigo A, Yahalom J, et al. . Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 28: 4570–74
    1. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–63
    1. Rubenstein JL, Fridlyand J, Abrey L, et al. . Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25: 1350–56. Epub 2007 Feb 20
    1. Soussain C, Hoang-Xuan K, Taillandier L, et al. . Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma. J Clin Oncol 2008; 26: 2512–18
    1. Le Bihan D, Turner R, Douek P, et al. . Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992; 159: 591–99
    1. Rowley HA, Grant PE, Roberts TP. Diffusion MR imaging: theory and applications. Neuroimaging Clin N Am 1999; 9: 343–61
    1. Le Bihan D, Breton E, Lallemand D, et al. . MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401–07
    1. Guo AC, Cummings TJ, Dash RC, et al. . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002; 224: 177–83
    1. Rubenstein J, Shen A, Batchelor T, et al. . Differential gene expression in central nervous system lymphoma. Blood 2009; 113: 266–67
    1. Rubenstein J, Fridlyand J, Shen A, et al. . Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107: 3716–23
    1. Blay JY, Conroy T, Chevreau C, et al. . High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864–71
    1. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986; 10: 611–17
    1. Matsumoto Y, Horiike S, Fujimoto Y, et al. . Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol 2007; 85: 333–37
    1. Ryken TC, Meeks SL, Pennington EC, et al. . Initial clinical experience with frameless stereotactic radiosurgery: analysis of accuracy and feasibility. Int J Radiat Oncol Biol Phys 2001; 51: 1152–58
    1. Roy S, Josephson SA, Fridlyand J, et al. . Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008; 26: 96–105
    1. Ducreux D, Wu RH, Mikulis DJ, et al. . Diffusion-weighted imaging and single-voxel MR spectroscopy in a case of malignant cerebral lymphoma. Neuroradiology 2003; 45: 865–68
    1. Stadnik TW, Chaskis C, Michotte A, et al. . Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001; 22: 969–76
    1. Kitis O, Altay H, Calli C, et al. . Minimum apparent diffusion coefficients in the evaluation of brain tumors. Euro J Radiol 2005; 55: 393–400
    1. Reiche W, Hagen T, Schuchardt V, et al. . Diffusion-weighted MR imaging improves diagnosis of CNS lymphomas: a report of four cases with common and uncommon imaging features. Clin Neurol Neurosurg 2007; 109: 92–101
    1. Toh CH, Castillo M, Wong AM, et al. . Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008; 29: 471–75
    1. O’Neill BP, Kelly PJ, Earle JD, et al. . Computer-assisted stereotaxic biopsy for the diagnosis of primary central nervous system lymphoma. Neurology 1987; 37: 1160–64
    1. Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system, result of treatment of 11 cases and review of the literature. J Neursosurg 1986; 65: 600–07
    1. O’Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc 1989; 64: 1005–20
    1. McAllister LD, Doolittle ND, Guastadisegni PE, et al. . Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51–61
    1. Moffat BA, Chenevert TL, Lawrence TS, et al. . Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005; 102: 5524–29
    1. Chenevert TL, Stegman LD, Taylor JM, et al. . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92: 2029–36
    1. Mardor Y, Pfeffer R, Spiegelmann R, et al. . Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003; 21: 1094–100
    1. Hamstra DA, Chenevert TL, Moffat BA, et al. . Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005; 102: 16759–64

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅